Cempra (NASDAQ: CEMP) announced positive topline results from a global, pivotal Phase 3 clinical trial of intravenous (IV) to oral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE